Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric MATCH: Selumetinib Subprotocol
NCT03213691Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of selumetinib in solid tumor, non-Hodgkin lymphoma (NHL) and histiocytic disorders, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 2 years. Started Oct 2017; status: completed.
02
Drugs
selumetinib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)histiocytic disorders
Beyond the preview
Go deeper on NCT03213691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03213691.